|
ZNF223 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.60258999999385E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.0467000000084E-05 |
| Normal-vs-Stage2 |
2.825700E-04 |
| Normal-vs-Stage3 |
1.60910000002179E-06 |
| Normal-vs-Stage4 |
2.39290000036974E-07 |
| Stage1-vs-Stage2 |
6.647400E-01 |
| Stage1-vs-Stage3 |
6.127900E-02 |
| Stage1-vs-Stage4 |
6.984600E-03 |
| Stage2-vs-Stage3 |
3.872800E-01 |
| Stage2-vs-Stage4 |
1.417240E-01 |
| Stage3-vs-Stage4 |
4.124000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.95048999999115E-05 |
| Normal-vs-AfricanAmerican |
5.443500E-03 |
| Normal-vs-Asian |
5.240400E-04 |
| Caucasian-vs-AfricanAmerican |
8.964400E-01 |
| Caucasian-vs-Asian |
6.976000E-01 |
| AfricanAmerican-vs-Asian |
8.903800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.1161999999908E-05 |
| Normal-vs-Female |
1.75274999999475E-05 |
| Male-vs-Female |
8.721600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.87209999999283E-05 |
| Normal-vs-Age(41-60Yrs) |
4.44750000000438E-05 |
| Normal-vs-Age(61-80Yrs) |
6.06530000002437E-07 |
| Normal-vs-Age(81-100Yrs) |
6.084500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.789400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.796400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.729800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.581500E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.769800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.886800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.077700E-03 |
| Classical-VS-Follicular |
1.497520E-02 |
| Classical-VS-Other |
4.742600E-01 |
| Classical-VS-Normal |
2.969900E-04 |
| Tall-VS-Follicular |
4.083000E-01 |
| Tall-VS-Other |
5.367200E-01 |
| Tall-VS-Normal |
3.38640000041579E-07 |
| Follicular-VS-Other |
9.201000E-01 |
| Follicular-VS-Normal |
3.48340000000391E-06 |
| Other-VS-Normal |
5.049800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.64929999999708E-05 |
| Normal-vs-N1 |
1.57800000000208E-06 |
| N0-vs-N1 |
1.698760E-01 |
|
|
